Lineage Cell Therapeutics (LCTX) Tops Q4 EPS by 2c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of $0.02. Revenue for the quarter came in at $2.9 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• H.B. Fuller (FUL) Tops Q2 EPS by 3c; Offers Outlook
• ICON plc (ICLR) PT Raised to $150 at BofA Securities